Can PGT-M PreventMonogenic DiseaseTransmission?

01 | Start With Inheritance: Will the Child Be Affected?

This step is more basic than deciding whether to use PGT-M. The common counseling error is to treat “inherits the variant” and “will be clinically affected” as the same statement; in X-linked disease, reduced penetrance and screened egg-source scenarios, those two statements may be very different.

Once X-linked dominant disease, de novo variants and mosaicism are added, the risk model becomes a practical decision table rather than a simple yes-or-no answer.

Two points are especially easy to miss. First, a de novo variant that arose in the father does not automatically make offspring risk low. If the variant is present in the germline, transmission can still be substantial. Second, paternal gonadal mosaicism should not be forced into a textbook 50% model; the risk depends on how much of the sperm population carries the variant.

02 | What PGT-M Does: Reduce a Known Familial Risk

PGT-M is meant to reduce transmission of a known monogenic condition when the familial pathogenic variant is clear and a reliable assay can be built.

It is not whole-genome clearance and should not be marketed as a universal way to improve pregnancy rates. HFEA public information lists more than 2,000 approved genetic conditions for PGT-M in the UK, while ASRM notes that many Mendelian disorders with a known genetic cause may be considered, subject to feasibility, family samples and haplotype construction.

The clinical chain usually runs from genetic counseling and record review to family sample collection, haplotyping or linkage analysis, IVF/ICSI, blastocyst biopsy, genetic analysis, embryo decision-making, prenatal confirmation and newborn follow-up.

03 | High Accuracy Is Not Zero Risk

ACOG and ASRM both emphasize that false-positive and false-negative results can occur in PGT. A negative or unaffected PGT-M result does not rule out every genetic problem in a newborn, and it does not cover microdeletions, microduplications, de novo variants, imprinting disorders or conditions outside the designed assay.

How accurate is it? Published summaries and center-level reports vary, but a common broad range is about 95%-98%. For established pregnancies, historical misdiagnosis has been reported below 1/200 (<0.5%), and modern approaches may be lower. That is still not zero and does not remove the need for prenatal confirmation.

Residual risk can come from allele drop-out, amplification failure, contamination, embryo or placental mosaicism, meiotic or mitotic recombination, sample identity error, incorrect donor or family information, and variants outside the tested region. Diagnostic success is also not the same as pregnancy rate or live-birth rate; implantation and live birth still depend on egg-source age, blastocyst number and embryo quality.

Should PGT-A be added?

The argument for adding PGT-A is stronger when the egg source is older, prior cycles produced few usable embryos, or the goal is to avoid transferring embryos that are monogenic-variant-negative but clearly aneuploid. The cautious view is that ACOG and ASRM do not support PGT-A as a routine add-on for every IVF patient. In donor-egg settings, benefit must be judged by embryo number, clinic policy and patient goals. Mosaic embryo reporting and a smaller transferable embryo pool also need to be discussed before testing.

04 | Probability: Embryo Number Changes the Chance

The practical formula is simple: each embryo has a probability p of meeting the transfer target; among n embryos, the probability of at least one target embryo is 1 - (1 - p)ⁿ.

Here, p may mean “not carrying the paternal AD variant,” or it may mean “both variant-free and euploid.” If euploidy is included, the extra assumption must be stated clearly. This is basic probability, not a live-birth promise.

Case 1: a 35-year-old autosomal dominant carrier

The core issue is not that he is single; it is that the father is heterozygous for an AD disorder, such as NF1 or another high-penetrance condition, and plans IVF/ICSI with a screened egg source and PGT-M.

Each embryo has about a 1/2 chance of inheriting the paternal pathogenic variant and a 1/2 chance of not inheriting it. With four testable blastocysts, the chance of at least one variant-free embryo is 1 - 0.5⁴ = 93.75%. If, as a teaching assumption, euploid probability is 60% and independent of the monogenic locus, the chance of an embryo being both variant-free and euploid is about 0.30; four embryos give 1 - 0.7⁴ = 75.99%.

Case 2: hemophilia A, an X-linked recessive condition

This case shows why “inherits the variant” and “has typical disease” are different. An affected father produces sperm carrying either X or Y. Daughters receive the paternal X; sons receive the paternal Y. If the egg source does not carry the relevant F8 variant, daughters usually carry the paternal variant, while sons usually do not inherit that paternal X-linked variant.

With a roughly even sex ratio, about half of children may carry the variant. But if the question is whether a child will have typical male hemophilia, the answer is different: sons are usually not affected by that paternal X variant, while daughters are usually carriers. Female carriers may still have clinical relevance, including bleeding symptoms in some cases because of skewed X inactivation.

Two additional common situations

Why single-partner AR carrier status often is not worth PGT-M: if the egg source has a residual carrier risk r after expanded screening, affected-child risk is approximately paternal transmission 1/2 × residual egg-source risk r × maternal transmission 1/2 = r/4. If r = 1/1000, affected risk is about 1/4000, or 0.025%.

How to model paternal gonadal mosaicism: if about 8% of sperm carry a particular AD variant, the chance of transmission is closer to 8% than to the classic 50%. The right wording is not simply “low risk,” but “not the classic 50%, yet still above background risk and requiring individual modelling.”

05 | Ethics, Law and Cost: Feasible Does Not Always Mean Appropriate

The strongest ethical indication for PGT-M remains serious, clear and verifiable monogenic disease. Its use has expanded into adult-onset disease, reduced penetrance and HLA matching, where the question shifts from “can it be done” to “should it be done.” Non-directive genetic counseling, patient autonomy and parallel discussion of alternatives are central.

Whether to transfer an embryo classified as affected is not answered by a slogan. It touches reproductive autonomy, the welfare of the future child, professional conscience and family context, and it requires clinic policy, informed consent and case-by-case judgment.

Regulation varies. The United States has no single national PGT-M regulator, while the UK HFEA requires approved conditions and licensed clinics. Sex information is generally limited to medical indications in many jurisdictions.

Timing is also longer than a standard IVF cycle. Genetic counseling and test development come first, followed by stimulation, biopsy, results and frozen embryo transfer. First-round commercial test development may take about 3-16 weeks; later cycles can be faster once the model is built.

06 | Pregnancy and Newborn Follow-Up

Once pregnancy is established, prenatal diagnosis should still be offered. ASRM, ESHRE and ACOG are aligned on this point: pregnancy after PGT-M should include counseling about rare misdiagnosis and the option of CVS or amniocentesis. If PGT-A was not performed, routine fetal aneuploidy screening or diagnosis should still be offered.

Follow-up should not stop at birth. If prenatal confirmation was not performed, targeted molecular testing after birth may be valuable. For X-linked disease, reduced penetrance, late-onset disease or clinically meaningful carrier status, family management and pediatric or specialty follow-up should be planned.

Current follow-up data are broadly reassuring, but should not be overstated. Available studies have not shown a major congenital malformation rate higher than IVF/ICSI controls, yet long-term outcomes by disease and testing pathway still require continued follow-up.

07 | One-Sentence Conclusion

Whether a man who carries or is affected by a monogenic variant will pass disease to a child depends on inheritance pattern, whether he is truly affected or only a carrier, egg-source genetics and whether a suitable PGT-M assay can be built.

The most common mistake is treating “only one partner is an AR carrier” and “the father is affected by AD or X-linked disease” as the same problem. The former often carries low affected-child risk after egg-source screening; the latter may carry a real vertical transmission risk and stronger PGT-M utility.

PGT-M can substantially reduce transmission of a known familial variant, but it is not a 100% block against all genetic, chromosomal, pregnancy or newborn risks.